Cargando…

Application of human lymphoid cells for the evaluation of antivirals against human adenovirus type 19: Zalcitabine has superior activity compared to cidofovir

Human adenovirus type 19 (HAdV-19) is a major cause of the epidemic keratoconjunctivitis. Outbreaks of keratoconjunctivitis are problematic to human health, especially for infants, the elderly, and immunocompromised individuals. However, the development of anti-HAdV drugs has been hampered by inconv...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakagawara, Kohsuke, Hayashi, Hironori, Kawaji, Kumi, Sasano, Mina, Kodama, Eiichi N
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7218274/
https://www.ncbi.nlm.nih.gov/pubmed/32345035
http://dx.doi.org/10.1177/2040206620921319
_version_ 1783532766029152256
author Nakagawara, Kohsuke
Hayashi, Hironori
Kawaji, Kumi
Sasano, Mina
Kodama, Eiichi N
author_facet Nakagawara, Kohsuke
Hayashi, Hironori
Kawaji, Kumi
Sasano, Mina
Kodama, Eiichi N
author_sort Nakagawara, Kohsuke
collection PubMed
description Human adenovirus type 19 (HAdV-19) is a major cause of the epidemic keratoconjunctivitis. Outbreaks of keratoconjunctivitis are problematic to human health, especially for infants, the elderly, and immunocompromised individuals. However, the development of anti-HAdV drugs has been hampered by inconvenient screening systems; therefore, development of a simple screening method is highly desirable. In this study, we identified that HAdV-19 can infect a human lymphoid cell line transformed with human T-cell leukemia virus (MT-2 cells). MT-2 cells supported HAdV-19 replication and showed apparent cytopathic effects within five days post-infection. Using a thiazolyl blue tetrazolium bromide (MTT)-based colorimetric assay on MT-2 cells, we were able to detect the anti-HAdV-19 activities of previously reported nucleoside/tide compounds, including (S)-1–(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (cidofovir), 2′,3′-dideoxycytidine (zalcitabine) and 3′-deoxy-3′-fluorothymidine (trifluridine). Compared with previous methods, this system represents a more simple and rapid method to screen anti-HAdV-19 agents.
format Online
Article
Text
id pubmed-7218274
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-72182742020-05-18 Application of human lymphoid cells for the evaluation of antivirals against human adenovirus type 19: Zalcitabine has superior activity compared to cidofovir Nakagawara, Kohsuke Hayashi, Hironori Kawaji, Kumi Sasano, Mina Kodama, Eiichi N Antivir Chem Chemother Short Communication Human adenovirus type 19 (HAdV-19) is a major cause of the epidemic keratoconjunctivitis. Outbreaks of keratoconjunctivitis are problematic to human health, especially for infants, the elderly, and immunocompromised individuals. However, the development of anti-HAdV drugs has been hampered by inconvenient screening systems; therefore, development of a simple screening method is highly desirable. In this study, we identified that HAdV-19 can infect a human lymphoid cell line transformed with human T-cell leukemia virus (MT-2 cells). MT-2 cells supported HAdV-19 replication and showed apparent cytopathic effects within five days post-infection. Using a thiazolyl blue tetrazolium bromide (MTT)-based colorimetric assay on MT-2 cells, we were able to detect the anti-HAdV-19 activities of previously reported nucleoside/tide compounds, including (S)-1–(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (cidofovir), 2′,3′-dideoxycytidine (zalcitabine) and 3′-deoxy-3′-fluorothymidine (trifluridine). Compared with previous methods, this system represents a more simple and rapid method to screen anti-HAdV-19 agents. SAGE Publications 2020-04-28 /pmc/articles/PMC7218274/ /pubmed/32345035 http://dx.doi.org/10.1177/2040206620921319 Text en © The Author(s) 2020 https://creativecommons.org/licenses/by/4.0/ Creative Commons CC BY: This article is distributed under the terms of the Creative Commons Attribution 4.0 License (https://creativecommons.org/licenses/by/4.0/) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Short Communication
Nakagawara, Kohsuke
Hayashi, Hironori
Kawaji, Kumi
Sasano, Mina
Kodama, Eiichi N
Application of human lymphoid cells for the evaluation of antivirals against human adenovirus type 19: Zalcitabine has superior activity compared to cidofovir
title Application of human lymphoid cells for the evaluation of antivirals against human adenovirus type 19: Zalcitabine has superior activity compared to cidofovir
title_full Application of human lymphoid cells for the evaluation of antivirals against human adenovirus type 19: Zalcitabine has superior activity compared to cidofovir
title_fullStr Application of human lymphoid cells for the evaluation of antivirals against human adenovirus type 19: Zalcitabine has superior activity compared to cidofovir
title_full_unstemmed Application of human lymphoid cells for the evaluation of antivirals against human adenovirus type 19: Zalcitabine has superior activity compared to cidofovir
title_short Application of human lymphoid cells for the evaluation of antivirals against human adenovirus type 19: Zalcitabine has superior activity compared to cidofovir
title_sort application of human lymphoid cells for the evaluation of antivirals against human adenovirus type 19: zalcitabine has superior activity compared to cidofovir
topic Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7218274/
https://www.ncbi.nlm.nih.gov/pubmed/32345035
http://dx.doi.org/10.1177/2040206620921319
work_keys_str_mv AT nakagawarakohsuke applicationofhumanlymphoidcellsfortheevaluationofantiviralsagainsthumanadenovirustype19zalcitabinehassuperioractivitycomparedtocidofovir
AT hayashihironori applicationofhumanlymphoidcellsfortheevaluationofantiviralsagainsthumanadenovirustype19zalcitabinehassuperioractivitycomparedtocidofovir
AT kawajikumi applicationofhumanlymphoidcellsfortheevaluationofantiviralsagainsthumanadenovirustype19zalcitabinehassuperioractivitycomparedtocidofovir
AT sasanomina applicationofhumanlymphoidcellsfortheevaluationofantiviralsagainsthumanadenovirustype19zalcitabinehassuperioractivitycomparedtocidofovir
AT kodamaeiichin applicationofhumanlymphoidcellsfortheevaluationofantiviralsagainsthumanadenovirustype19zalcitabinehassuperioractivitycomparedtocidofovir